The Impact of a Concurrent Exercise Program With Metformin and Rosiglitazone on Glycemic Control by Horner, Robert E
Pacific University
CommonKnowledge
School of Physician Assistant Studies Theses, Dissertations and Capstone Projects
Summer 8-10-2013
The Impact of a Concurrent Exercise Program
With Metformin and Rosiglitazone on Glycemic
Control
Robert E. Horner
Follow this and additional works at: http://commons.pacificu.edu/pa
Part of the Medicine and Health Sciences Commons
This Capstone Project is brought to you for free and open access by the Theses, Dissertations and Capstone Projects at CommonKnowledge. It has
been accepted for inclusion in School of Physician Assistant Studies by an authorized administrator of CommonKnowledge. For more information,
please contact CommonKnowledge@pacificu.edu.
Recommended Citation
Horner, Robert E., "The Impact of a Concurrent Exercise Program With Metformin and Rosiglitazone on Glycemic Control" (2013).
School of Physician Assistant Studies. Paper 447.
The Impact of a Concurrent Exercise Program With Metformin and
Rosiglitazone on Glycemic Control
Abstract
Background: Type 2 diabetes mellitus is a growing disorder throughout the world. Two of the major
treatment modalities are used concurrently to fight inadequate glycemic control is exercise and diabetic
medications. Metformin and rosiglitazone are diabetic medications known to improve glycemic control.
Metformin lowers exercise capacity in diabetics while rosiglitazone improves exercise capacity. Given the
impact of metformin and rosiglitazone on exercise capacity, the overall improvements in glycemic control,
when used with a concurrent exercise program, needs to be examined.
Method: An exhaustive search of available medical literature was conducted using Medline-OVID, EBSCO-
CINAHL and Web of Science using the keywords: type 2 diabetes mellitus, metformin, rosiglitazone, insulin
resistance and exercise. Relevant articles were assessed for quality using GRADE.
Results: The search resulted in two studies that met inclusion criteria to be in this systematic review. The first
study was a controlled trial with 32 participants and demonstrated that metformin does not accentuate the
insulin sensitivity of exercise alone. The second study was a randomized controlled trial with 100 participants
and demonstrated that rosiglitazone plus exercise improved glycemic control more than either treatment
alone.
Conclusion: Although the amount and quality of evidence on the subject is lacking, these results have
implications for clinical practice when individualizing patient treatment plans. Metformin and exercise do not
have additive effects on glycemic control while rosiglitazone and exercise complement each other and do
provide additive effects over time on glycemic control. Further research is needed to expand on the
interactions between exercise and these diabetic medications on glycemic control, HbA1c and fasting glucose
levels.
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Abstract   
 
Background:  Type 2 diabetes mellitus is a growing disorder throughout the world.  Two 
of the major treatment modalities are used concurrently to fight inadequate glycemic 
control is exercise and diabetic medications.  Metformin and rosiglitazone are diabetic 
medications known to improve glycemic control.  Metformin lowers exercise capacity in 
diabetics while rosiglitazone improves exercise capacity.  Given the impact of metformin 
and rosiglitazone on exercise capacity, the overall improvements in glycemic control, 
when used with a concurrent exercise program, needs to be examined. 
 
Method:  An exhaustive search of available medical literature was conducted using 
Medline-OVID, EBSCO-CINAHL and Web of Science using the keywords:  type 2 
diabetes mellitus, metformin, rosiglitazone, insulin resistance and exercise.  Relevant 
articles were assessed for quality using GRADE. 
 
Results:  The search resulted in two studies that met inclusion criteria to be in this 
systematic review.  The first study was a controlled trial with 32 participants and 
demonstrated that metformin does not accentuate the insulin sensitivity of exercise alone.  
The second study was a randomized controlled trial with 100 participants and 
demonstrated that rosiglitazone plus exercise improved glycemic control more than either 
treatment alone. 
 
Conclusion: Although the amount and quality of evidence on the subject is lacking, these 
results have implications for clinical practice when individualizing patient treatment 
plans.  Metformin and exercise do not have additive effects on glycemic control while 
rosiglitazone and exercise complement each other and do provide additive effects over 
time on glycemic control.  Further research is needed to expand on the interactions 
between exercise and these diabetic medications on glycemic control, HbA1c and fasting 
glucose levels. 
 
Keywords:  Type 2 diabetes mellitus, metformin, rosiglitazone, exercise, insulin 
resistance and glycemic control. 
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The Impact of a Concurrent Exercise Program With Metformin and Rosiglitazone 
on Glycemic Control  
BACKGROUND 
 Insulin resistance and impaired insulin secretion leads to the hyperglycemic state 
that develops into type 2 diabetes mellitus (T2DM). Treatment regimens include both 
exercise and diabetic medications to help control glucose levels and improve insulin 
sensitivity.  As little as one week of vigorous exercise can improve peripheral insulin 
sensitivity and suppress hepatic glucose production. 1 Therefore, it is important to include 
exercise as a treatment option for those with and those at risk of developing T2DM.   
Metformin and rosiglitazone are common diabetes medications.  Metformin has been 
found to improve glycemic control, decrease cardiovascular disease risk factors and 
decrease insulin resistance. 2 Similarly, rosiglitazone has been found, in patients with 
T2DM, to improve insulin responsiveness. 3 Because these therapeutic drugs are 
prescribed simultaneously with exercise, it is important to understand how these drugs 
might affect the patient's ability to exercise. 
 Previous studies have looked at how metformin and rosiglitazone may increase or 
decrease a patient's ability to exercise.  In one study, metformin was found to increase 
patient's heart rate at submaximal exercise and increase perceived exertion, leading to a 
decrease in patients selected exercise intensity. 4 Another study showed that peak heart 
rate was reduced significantly along with peak ventilation, peak oxygen uptake, peak 
respiratory exchange rate and exercise duration while taking metformin. 5 If a patient 
taking metformin has an increased heart rate doing submaximal exercise but a decreased 
heart rate doing maximal exercise, their overall ability to exercise will be decreased.  
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Conversely, rosiglitazone has been found to actually increase maximal oxygen 
consumption and improve exercise capacity in patients with T2DM. 6 One study shows 
that diabetic patients have a decrease in blood flow and endurance during isometric 
exercise that could be partially reversed with treatment using rosiglitazone for three 
months. 7 Therefore it seems that metformin limits exercise capabilities while 
rosiglitazone can improve them in diabetic patients.  It is important to understand how 
exercise affects the results of metformin and rosiglitazone because exercise is prescribed 
concurrently with diabetic medications in the hope of additive affects on glycemic 
control. The purpose of this systematic review is to determine if a concurrent, supervised 
exercise regimen with metformin or rosiglitazone affects the drug's ability to improve 
insulin resistance in patients with or at risk of developing T2DM. 
METHODS 
 An exhaustive literature search using the search engines Medline-OVID, EBSCO-
CINAHL and Web of Science was performed.  The following search terms were used on 
the Medline-OVID database: "type 2 diabetes mellitus AND exercise (focus)," AND 
"metformin OR rosiglitazone."  The following search terms were used on the EBSCO-
CINAHL database: "diabetes," AND "exercise," AND "insulin sensitivity," AND 
"metformin OR rosiglitazone."  The following search terms were used on Web of 
Science: "insulin sensitivity," AND "exercise," AND "diabetes mellitus type 2" AND 
"metformin OR rosiglitazone." 
 Inclusion criteria for articles included in the systematic review included those 
using metformin or rosiglitazone or a combination of the two drugs with a concurrent 
exercise regimen and measuring glycemic indices.  Articles were excluded if they were 
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not published in English, if exercise was only used at the beginning and end of the study, 
if it focused on medications other than metformin or rosiglitazone and if they did not 
measure insulin sensitivity or fasting glucose levels. 
 Relevant articles were assessed for quality using the Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE). 8 
RESULTS 
 The Medline-OVID search resulted in a total of 25 articles, while the EBSCO-
CINAHL search resulted in a total of 15 articles and the Web of Science search resulted 
in a total of 48 articles.  Once articles were screened for inclusion criteria, exclusion 
criteria, and duplicates were accounted for, two articles were deemed of high relevance 
for this systematic review.  The two studies included in the systematic review are detailed 
in Table I. 
Independent and Combined Effects of Exercise Training and Metformin  
 In 2011, Malin et al 9from the University of Massachusetts, Amherst, conducted a 
study to determine the independent and combined effects of exercise training and 
metformin on insulin sensitivity in individuals with prediabetes.  The study participants 
were 32 individuals with impaired glucose tolerance who were recruited from the local 
community via flyers and newspaper advertisements.  The article does not mention any 
randomization of treatment.  Participants were assigned to one of four interventions: 
placebo, metformin, exercise training with placebo, or exercise training with metformin.  
Participants included 12 males and 20 females between the ages of 35 and 65, and 
included both pre and postmenopausal women.  Participants were enrolled in the study if 
they were nonsmoking, weight stable, free of cardiovascular disease or diabetes, had any 
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contraindications to metformin, and were not taking dietary supplements or medications 
that would affect insulin sensitivity.  As a result of the community that they were 
recruited from, the racial makeup of the participants included 27 Caucasians, three 
African Americans, and two Hispanics.  The study lasted a total of 12 weeks. 9   
 A double-blind design was used to distribute pills and subjects taking the pills 
were told to do so with food to minimize potential side effects.  Initially subjects were 
treated with 500 mg/day of metformin and the dose was increased by 500 mg/day each 
week until reaching a clinical dose of 2000 mg/day by week four.  The clinical dose was 
taken for the remaining eight weeks of the 12-week study.  Exercise was supervised three 
days a week for 60-75 minutes per session.  Aerobic and resistance exercise was 
performed on the first and third day of each week, while only aerobic exercise was 
performed on the second day of exercise each week to minimize muscle soreness.  The 
first five minutes was a warm up on a cycle ergometer, followed by 45 minutes of cycling 
at 70% baseline peak heart rate.  Resistance exercise was performed at 70% the subjects 
baseline one repetition maximum.  Once a participant could lift two sets of 12 repetitions 
with proper form, weight was increased by about five percent.  All major muscle groups 
used during chest press, latissimus pull-down, leg press, bicep curl, triceps push-down 
and upright row exercises were targeted by the resistance training. 9 
 Measurements of insulin, glucose, C peptide, nonesterified fatty acids and stable 
isotope enrichment were performed at the beginning and end of the study using a 
euglycemic hyperinsulinemic clamp.  Each of the interventions resulted in 13-25% lower 
fasting insulin concentrations (P < 0.05) yet there was no difference among the 
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interventions.  Both hepatic glucose production and insulin sensitivity were unaffected 
after any treatment. 9 
Exercise Training Ameliorates the Effects of Rosiglitazone 
 In 2009, Kadoglou et al 10 conducted a study to determine how exercise training 
interacts with rosiglitazone to improve cardiovascular risk factors in patients with T2DM.  
The study participants were 100 white patients with T2DM, between the ages of 50 and 
70 years, and were recruited from an outpatient diabetic clinic.  The patients eligible for 
the study had been receiving metformin and gliclazide treatment for at least six months 
without adequate glycemic control.  Patients were ineligible if they had diabetic vascular 
complications, chronic heart failure, liver or renal impairment, uncontrolled hypertension, 
arrhythmias, orthopedic problems or life threatening diseases.  They were also excluded 
if they were on lipid lowering medication, hormone replacement therapy, insulin, 
thiazolidinedione treatment or were active smokers.  The study lasted 12 months and the 
patients were randomly assigned to the following age and sex matched groups: control 
group, addition of rosiglitazone, adjunctive exercise program, and addition of 
rosiglitazone and adjunctive exercise program.  The control group maintained their 
current habitual activities while groups receiving rosiglitazone received 8 mg/day.  
Patients were assigned through a computer generated random list on a database protected 
by a password. 10 
 Patients that were assigned to receive exercise treatment attended the same fitness 
center four times a week to perform aerobic exercise.  The intensity of the exercise 
sessions was individuated by an initial ergocycle test.  Each session was 45-60 minutes 
long including a 10 minute warm up and five minute cool down.  During the course of the 
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first month the workload was increased until subjects achieved 50% to 80% peak oxygen 
consumption for 45 minutes.  Exercise included walking or running on a treadmill, 
cycling and calisthenics involving large muscle groups.  Exercise remained constant until 
the eighth month, when subjects could continue the exercise in a self-controlled lifestyle 
program including brisk walking, jogging and daily activities for more than 150 minutes 
per week.  Patients kept their own personal diary of activity records that were checked 
every two weeks for compliance.  This study showed that despite going from a structured 
exercise program to a self-controlled exercise program, the exercise treated patients were 
able to maintain the exercise related benefits from the initial eight months and have 
persistent benefits in glycemic control. 10     
 Blood samples were obtained at baseline and at the end of the study.  These blood 
samples looked at glucose, hemoglobin A1c (HbA1c) and insulin levels among many 
other outcomes.  HbA1c levels changed most drastically in the rosiglitazone and exercise 
group with a -1.52% +/- 0.91% from baseline.  Exercise alone resulted in a HbA1c  -
0.29% +/- 0.57% from baseline while rosiglitazone alone was -0.83% +/- 0.89% from 
baseline.  The rosiglitazone with exercise group had the most improved glycemic control, 
accounting for 76.7% of the patients in the study who reached the glycemic target of 
having a HbA1c below seven percent at the end of the study. 10  
DISCUSSION 
  The findings from these studies should be considered when dealing with patients 
with or at risk of developing T2DM.  Metformin is shown to limit exercise capacity while 
rosiglitazone is shown to actually improve exercise capacity in those with T2DM.  Over 
time, these effects may interact so that metformin and exercise do not have additive 
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affects on glycemic control while rosiglitazone plus exercise does.  This knowledge is 
important when deciding how to individualize treatment for a patient with T2DM.  If a 
patient is motivated to begin a supervised exercise program, it may be more beneficial to 
prescribe rosiglitazone instead of metformin.  If this patient were to receive metformin, it 
has the potential to increase resting heart rate and decrease peak heart rate, limiting their 
ability to exercise.  This patient may become less motivated to exercise, and even if they 
were to exercise, the affects of the two treatment modalities together may not be additive.  
This same patient on rosiglitazone will have improvements in exercise capacity, which 
may result in a more motivated patient.  The combined treatment modalities of exercise 
and rosiglitazone will also have additive affects on glycemic control by increasing 
exercise capacity and motivation, improving insulin secretion and sensitivity, decreasing 
HbA1c and lowering fasting glucose levels.   
  
Independent and Combined Effects of Exercise Training and Metformin 
 This study found that the addition of metformin to exercise training does not 
accentuate the effects on the whole body insulin sensitivity of exercise alone. 9 
 The quality of evidence from this study is very low.  This study has a small 
sample size with only 32 participants.  It also does not mention any form of 
randomization when allocating group assignments.  The small study size that is 
characteristic of that community, which is mainly Caucasian, is not characteristic of all 
communities.  This study also does not look at an equal number of men and women or the 
younger population, which has a rapidly growing risk of developing T2DM.  The study 
period of 12 weeks is too short to see how much the treatment modalities interact. 9     
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 The article states that no potential conflicts of interest were reported relevant to 
this article.  However, there are many areas in which bias may have affected this study.  
Selection bias may have occurred because subjects of the study were recruited via flyers 
and newspaper advertisements.  There is no mention of these flyers or advertisements in 
languages other than English.  Furthermore, there was no mention of randomization in 
the study.  Blinding occurred during pill distribution to patients, but it impossible to blind 
them to the fact that they are either doing an exercise regimen or not. 9   
Exercise Training Ameliorates the Effects of Rosiglitazone 
 This study found that the group with greatest benefit on glycemic control was 
exercise training in addition to rosiglitazone compared to either treatment alone. 10   
 The quality of evidence from this study is low.  Participants of the study were 
randomized and there were a total of 89 people analyzed after loss to follow up.  The 
study lasted 12 months, which allowed for the treatments to interact for a longer period of 
time. 10   
 There are limitations to this study.  All of the study participants in this study were 
Caucasian and belonged to an older age group.  This limits the study results to a fairly 
specific population group.  Also, to measure insulin sensitivity they used a homeostasis 
model assessment (HOMA-IR) that reflects both peripheral and hepatic insulin 
sensitivity.  Furthermore, the last four months of the exercise regimen was self reported 
and leaves room for reporting bias from the patients.  Also, insulin sensitivity 
measurements were not taken at the eight month mark so there is no way to determine 
how the period of self controlled exercise affected the glycemic controls over the last four 
months of the study. 10   
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CONCLUSION 
 There are many studies exhibiting the interactions between metformin and 
rosiglitazone and the ability of patients to exercise but there are few studies analyzing the 
interactions between exercise and diabetic medications over time and their affects on 
diabetic disease markers such as insulin sensitivity and HbA1c.  These studies show that 
rosiglitazone has additive effects with exercise while metformin does not.  The evidence 
on the subject of this review is lacking and the quality of the evidence is not sufficient to 
make strong conclusions.    
   Future research is needed to confirm and expand on the results of the studies in 
this review.  The studies should be over a longer period of time, with a greater number of 
study participants to determine how large of an effect the interaction between treatment 
modalities is.  Studies should focus on both younger populations and older ones.  
Randomization of participants needs to have a greater focus, along with blinding and 
concealment when possible.  HbA1c and fasting glucose levels should be outcomes that 
are measured since those are the measurements used to determine the diagnosis of 
T2DM. 
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Table I. Characteristics of Reviewed Studies 
 
Study 
Total 
subjects 
at the 
beginning 
of study 
Total 
subjects 
analyzed 
at end of 
study 
Follow 
up 
period 
Description 
of loss to 
follow-up 
Intervention 
Groups Randomization 
Allocation 
Concealment 
Blinding 
of 
outcome 
assessors 
Quality 
of 
Evidence 
(GRADE) 
Malin et 
al 9  32 Unclear 
12 
weeks Unclear 
Control, 
Metformin, 
exercise with 
placebo, exercise 
with metformin Unclear Adequate Unclear 
Very 
Low* 
Kadoglou 
et al 10 100 89 
12 
months Yes 
 
 
Control, add on 
rosiglitazone, 
adjunctive exercise 
program, add on 
rosiglitazone and 
adjunctive exercise 
program Adequate Unclear Unclear Low# 
 
*Quality is very low due to unclear randomization and loss to follow up, small study size and short study duration 
#Quality is low because it only looked at white patients, concealment was unclear and there was no data collection between changing 
exercise regimens 
